Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

"As a result of prudent cash control, we reconfirm that the cash burn for the year ended December 31, 2008 will remain at the lower end of $25 to $30 million guidance provided earlier this year," said Stuart Grant, BioCryst's Chief Financial Officer. "We have implemented strategic initiatives, including a recent 20 percent reduction in our workforce, to focus the Company's resources on the execution of our late-stage clinical trials and the development of our most promising pre-clinical compounds. We have full funding of our peramivir program through Phase 2 clinical trials from HHS and a strong cash position that will allow us to execute on our plan without depending on the capital markets."

"We have recently made significant advancements in our clinical programs and are encouraged by the positive peramivir efficacy data reported in the Phase 2 study we conducted in subjects with influenza requiring hospitalization, and the Phase 2 study in subjects with acute uncomplicated influenza conducted by our partner, Shionogi & Co., Ltd.," said Jon Stonehouse, President and Chief Executive Officer of BioCryst. "Over the next year, we have several key value-driving milestones for both our peramivir and PNP programs and remain committed to advancing our products towards market."

Corporate Update

-- A poster entitled "A Double-Blind, Placebo-Controlled Study of

Intravenous Peramivir in Acute Influenza Patients" was presented at

the 48th Annual Interscience Conference on Antimicrobial Agents and

Chemotherapy (ICAAC), detailing the results of a Shionogi & Co.,

Ltd.-sponsored, placebo-controlled, Phase 2 study of intravenous (i.v.)

peramivir, a neuraminidase inhibitor, in outpatients with acute,

uncomplicated influenza. The study met its primary endpoint of time to

alleviation of symptoms for both the 300 mg dose (p=0.0046) and 600 mg

dose (p=0.0046) (hazard ratios we
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... ... , ... (PRWEB) October 21, 2009 -- iLife Americas, LLC, a leading developer and marketer of ... its line of iLife wellness and therapeutic products. Officially opened on September 1, 2009, ...
... -- China Medical Technologies,Inc. (the "Company") (Nasdaq: CMED ), ... advanced in-vitro diagnostic,products, today announced that it will attend the ... October 31, 2009 in Chengdu,China. , , ... China International Medical Equipment Fair, Date: ...
... created a new material that would allow a fingernail-size ... DVDs or 250 million pages of text, far exceeding ... Led by Dr. Jagdish "Jay" Narayan, John C.C. Fan ... director of the National Science Foundation Center for Advanced ...
Cached Biology Technology:iLife Americas, LLC Enters U.S. Wellness and Therapeutic Markets 2China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China 2New material could boost data storage, save energy 2
(Date:7/31/2015)... , July 31, 2015 The 10 th ... be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary this ... of the world,s most influential annual meetings in the ,omics, ... enjoyable scientific gatherings. ICG-10 focuses on recent ...
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
(Date:7/21/2015)... NEW YORK , July 21, 2015 /PRNewswire/ ... critical systems, as seen in the recent U.S. ... enterprises a solution to the infosec conundrum, but ... data is stored. To address this dilemma, Biometrics-as-a-Service ... of its Biometric Tokenization SDK for third party ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... CITY After years of working toward this goal, scientists ... isolate cancer stem cells in tumors so they can target ... A research team at the University of Oklahoma led ... a particular protein only appears in stem cells. Until now, ...
... KNOXVILLE -- Two research groups from the University of ... National Science Foundation to create new graduate research and ... The grants, called Integrative Graduate Education and Research Traineeships, ... graduate students to UT Knoxville for two unique programs ...
... University of Nottingham are to investigate the effect of nutrients ... of keeping up our strength as we get old. ... and Health in Derby, want to know what sort of ... to slow down the natural loss of skeletal muscle with ...
Cached Biology News:UT Knoxville wins 2 $3M National Science Foundation research and education grants 2A stronger future for the elderly 2
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... Ambions 96 well Magnetic-Ring Stand is designed ... well U-bottom microplates. The stand has a ... well microtiter plate footprint. The use of ... fast and easy magnetic separation. With this ...
Request Info...
Biology Products: